Scroll Down
Photo for illustrative purposes only. Not actual patient.
About 1 in 100 SEXUALLY
ACTIVE
ADULTS HAS EGW
Photo for illustrative purposes only. Not actual patients.
Photo for illustrative purposes only. Not actual patients.
Photo for illustrative purposes only. Not actual patients.
Photo for illustrative purposes only. Not actual patients.
Scroll Down
Photo for illustrative purposes only. Not actual patient.
The strains of HPV that cause EGW are low-risk HPV strains that do not cause cancer.1,2
Although for some patients EGW can be very obvious, for others they can be asymptomatic, so patients may unknowingly transmit the viruses that cause EGW.1,3
EGW may appear weeks or months after acquiring an HPV infection. Or they may never appear, making it difficult to know exactly when or from whom a person contracted EGW.1,3
Using a condom during sex may help reduce the risk of getting HPV, but a condom does not always cover all the affected skin—so it may not completely protect your patient and his or her partner.1
Treatment may help alleviate the symptoms of EGW, although treatment does not cure the HPV infection itself, and recurrence is common.1
Photo for illustrative purposes only. Not actual patient.
Photo for illustrative purposes only. Not actual patients.
Ask about number of partners and risk factors of those partners.4
Photo for illustrative purposes only. Not actual patients.
Encourage patients to practice safe sex, such as abstinence, monogamy, and condom use.1,4
Identify risk factors for STDs and try to determine the patient's perception of his or her own risk as well as his or her partner's risk.4
Inquire about testing for STDs and assess history of STDs.4
Determine risk of becoming pregnant or fathering a child; counsel accordingly, including offering information on birth control or making a referral if appropriate.4
Additional information from your patients may be needed, but "The 5 Ps" may lay the foundation for an open and honest dialogue about sexual health.
Low discontinuation rate
Only 2.3% of VEREGEN® patients discontinued treatment due to local adverse events.5
The majority of adverse events were mild or moderate local application site reactions.6 In the overall study population, the maximum mean severity of erythema, erosion, edema, and induration was observed by week 2 of treatment.7
Clearance rates of EGW*
Complete Clearance
(vs 35.3% for vehicle)7
Sustained Clearance
(vs 94.2% for vehicle) at 12 weeks post treatment7
*The effectiveness of VEREGEN® was assessed in two phase 3, randomized, double-blind, vehicle-controlled studies (United States and international) of immunocompetent male and female patients (N=604) aged 18 years and older who had EGW. VEREGEN® or vehicle was applied 3 times daily until complete clinical (visual) clearance of all EGW (baseline and new) or up to 16 weeks. Those patients who experienced complete clearance of all warts were followed for a 12-week, treatment-free period to assess sustained clearance.6,7
Proven Patient Success With VEREGEN® Ointment for the Treatment of EGW
Week 1 (baseline)
Week 12
REVEAL ACTUAL PHOTOS
Male patient from clinical trial at baseline and at week 12 of therapy with VEREGEN® Ointment, 15%.
Photos provided with permission from Silvio Tatti, MD, PhD, First Chair Gynecology, Hospital de Clinicas, Buenos Aires, Argentina.
Week 1 (baseline)
Week 16
Female patient from clinical trial at baseline and at week 16 of therapy with VEREGEN® Ointment, 15%.
Week 1 (baseline)
Week 16
Male patient from clinical trial at baseline and at week 16 of therapy with VEREGEN® Ointment, 15%.
Week 1 (baseline)
Week 16
Male patient from clinical trial at baseline and at week 16 of therapy with VEREGEN® Ointment, 15%.
First set of photos provided with permission from Silvio Tatti, MD, PhD, First Chair Gynecology, Hospital de Clinicas, Buenos Aires, Argentina.
Second set of photos provided with permission from Eggert Stockfleth, Director of the Skin Cancer Center, University Hospital Charite, Berlin, Germany.
Third set of photos provided with permission from Theodore Rosen, MD, Professor of Dermatology, Baylor College of Medicine, Houston, Texas.
It's easy to get samples of VEREGEN® ointment. Simply complete the form and fax it back.
The ANI Pharmaceuticals Derm Copay Savings PROGRAM can help eligible patients save on their VEREGEN® copays. Patients may pay as little as $0 for their prescription.†
The program requires patient enrollment. Instruct patients to visit anipharmaceuticals.com to enroll in the program.
†Eligibility rules apply: For qualified patients only. Maximum benefits may apply.
For full details regarding the ANI Derm Copay Savings Program, visit www.anipharmaceuticals.com or call 1-844-396-8097.
VEREGEN® (sinecatechins) has not been evaluated to treat urethral, intra-vaginal, cervical, rectal, or intra-anal human papilloma viral disease and should not be used to treat these conditions. Avoid use of VEREGEN® on open wounds.
Avoid exposure of VEREGEN®-treated areas to sun/UV-light because VEREGEN® has not been tested under these circumstances. Safety and efficacy of VEREGEN® have not been established in immunosuppressed patients or patients under 18 years of age, or pregnant women, or for the treatment of external genital and perianal warts beyond 16 weeks or for multiple treatment courses.
The most common adverse reactions are local skin and application site reactions including (incidence ≥20%) erythema, pruritus, burning, pain/discomfort, erosion/ulceration, edema, induration, and rash vesicular.
Please see Full Prescribing Information for VEREGEN®.
You are encouraged to report negative side effects of prescription drugs to the Food and Drug Administration (FDA). Please visit www.fda.gov/medwatch or call 1-800-FDA-1088.
VEREGEN® is indicated for the topical treatment of external genital and perianal warts (Condylomata acuminata) in immunocompetent patients 18 years and older.
References: 1. Genital HPV infection. CDC Fact Sheet. Centers for Disease Control and Prevention website. https://www.cdc.gov/std/hpv/HPV-FS-July-2017.pdf. Accessed April 16, 2019. 2. Genital warts: overview. American Academy of Dermatology website. https://www.aad.org/public/diseases/contagious-skin-diseases/genital-warts. Accessed April 15, 2019. 3. Genital warts. Centers for Disease Control and Prevention website. https://www.cdc.gov/healthcommunication/toolstemplates/entertainmented/tips/GenitalWarts.html. Accessed April 17, 2019. 4. A guide to taking a sexual history. Centers for Disease Control and Prevention website. https://www.cdc.gov/std/treatment/SexualHistory.pdf. Published 2011. Updated March 14, 2014. Accessed April 15, 2019. 5. Data on file, Fougera. 6. Stockfleth E, Beti H, Orasan R, et al. Topical Polyphenon® E in the treatment of external genital and perianal warts: randomized controlled trial. Br J Dermatol. 2008;158(6):1329-1338. 7. VEREGEN® Ointment, 15% [prescribing information, Rev. 2018]. Melville, NY: PharmaDerm, a division of Fougera Pharmaceuticals Inc.
ANI Pharmaceuticals is not responsible for the privacy policy, the content, or the accuracy of any websites accessed through a link on the veregen.com site. A link to other websites does not constitute an endorsement of ANI Pharmaceuticals or the linked site, its products, or services.
The browser window or tab for veregen.com will remain open. To return to veregen.com at any time, close this tab or window.
